AI Article Synopsis

  • PTP1B(-/-) mice resist diet-induced obesity due to heightened leptin sensitivity and increased energy expenditure.
  • Elevated alpha1 and alpha2 AMPK activity in muscle and brown adipose tissue is linked to the absence of PTP1B, with effects primarily mediated by neurons.
  • Inhibition of PTP1B leads to lower hypothalamic AMPK activity but promotes increased expression of genes that enhance mitochondrial function and energy metabolism, ultimately supporting leanness.

Article Abstract

PTP1B(-/-) mice are resistant to diet-induced obesity due to leptin hypersensitivity and consequent increased energy expenditure. We aimed to determine the cellular mechanisms underlying this metabolic state. AMPK is an important mediator of leptin's metabolic effects. We find that alpha1 and alpha2 AMPK activity are elevated and acetyl-coenzyme A carboxylase activity is decreased in the muscle and brown adipose tissue (BAT) of PTP1B(-/-) mice. The effects of PTP1B deficiency on alpha2, but not alpha1, AMPK activity in BAT and muscle are neuronally mediated, as they are present in neuron- but not muscle-specific PTP1B(-/-) mice. In addition, AMPK activity is decreased in the hypothalamic nuclei of neuronal and whole-body PTP1B(-/-) mice, accompanied by alterations in neuropeptide expression that are indicative of enhanced leptin sensitivity. Furthermore, AMPK target genes regulating mitochondrial biogenesis, fatty acid oxidation, and energy expenditure are induced with PTP1B inhibition, resulting in increased mitochondrial content in BAT and conversion to a more oxidative muscle fiber type. Thus, neuronal PTP1B inhibition results in decreased hypothalamic AMPK activity, isoform-specific AMPK activation in peripheral tissues, and downstream gene expression changes that promote leanness and increased energy expenditure. Therefore, the mechanism by which PTP1B regulates adiposity and leptin sensitivity likely involves the coordinated regulation of AMPK in hypothalamus and peripheral tissues.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725736PMC
http://dx.doi.org/10.1128/MCB.01914-08DOI Listing

Publication Analysis

Top Keywords

ptp1b-/- mice
16
ampk activity
16
peripheral tissues
12
energy expenditure
12
ampk
10
hypothalamic ampk
8
increased energy
8
activity decreased
8
decreased hypothalamic
8
leptin sensitivity
8

Similar Publications

Type 2 diabetes mellitus (T2DM), a metabolic disorder, has the hallmarks of persistent hyperglycemia, insulin resistance, and dyslipidemia. Protein-tyrosine phosphatase 1B (PTP1B) was found to be overexpressed in many tissues in the case of T2DM and involved in the negative regulation of insulin signaling. So, PTP1B inhibition can act as a therapeutic target for T2DM.

View Article and Find Full Text PDF

Ansofaxine suppressed NSCLC progression by increasing sensitization to combination immunotherapy.

Int Immunopharmacol

December 2024

School of Medicine, Guizhou University, Guiyang 550025, China; NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China. Electronic address:

Introduction: Depression negatively impacts the prognosis of various cancers, including lung cancer, by influencing antitumor immune responses and impairing immune cell function. Antidepressants may modulate the tumor immune microenvironment, enhancing immunotherapy efficacy. However, the specific mechanisms remain unclear.

View Article and Find Full Text PDF

Pharmacological PTP1B inhibition rescues motor learning, neuroinflammation, and hyperglycaemia in a mouse model of Alzheimer's disease.

Exp Neurol

December 2024

Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, Foresterhill, University of Aberdeen, Aberdeen, AB25 2ZD, UK.

Background: Patients with Alzheimer's Disease (AD) frequently suffer from comorbidities such as type 2 diabetes mellitus (T2DM), accompanied by shared common pathologies such as increased inflammation and impaired glucose homeostasis. Beta-secretase 1 (BACE1), the rate limiting enzyme in AD associated beta-amyloid (Aβ) production, is also implicated in metabolic dysfunction and can increase central and peripheral protein levels of protein tyrosine phosphatase 1B (PTP1B). PTP1B is a validated target in diabetes and obesity, and is a neuroinflammatory regulator involved in degenerative processes.

View Article and Find Full Text PDF

Allosteric inhibition of PTP1B by bromocatechol-chalcone derivatives.

Eur J Med Chem

January 2025

State Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, Shandong, PR China; Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao, 266237, Shandong, PR China. Electronic address:

Article Synopsis
  • Researchers are developing allosteric inhibitors as potential hypoglycemic drugs targeting the enzyme PTP1B to fight diabetes mellitus.
  • These inhibitors work by occupying a specific hydrophobic site (BB site) on PTP1B, keeping a loop in an open position, which prevents the enzyme from performing its normal dephosphorylation functions.
  • One impressive compound, LXQ-87, shows promise by effectively lowering blood glucose levels and enhancing glucose tolerance in diabetic mice while also improving insulin resistance.
View Article and Find Full Text PDF

PTP1B Modulates Carotid Plaque Vulnerability in Atherosclerosis Through Rab5-PDGFRβ-Mediated Endocytosis Disruption and Apoptosis.

CNS Neurosci Ther

November 2024

Laboratory of Computational Biology and Machine Intelligence, National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China.

Background: Protein tyrosine phosphatase 1B (PTP1B) is a protein tyrosine phosphatase and modulates platelet-derived growth factor (PDGF)/platelet-derived growth factor receptor (PDGFR) signaling in vascular smooth muscle cells (VSMCs) via endocytosis. However, the related molecular pathways that participated in the interaction of endo-lysosome and the trafficking of PDGFR are largely unknown. This study aims to determine the subcellular regulating mechanism of PTP1B to the endo-lysosome degradation of PDGFR in atherosclerotic carotid plaques, thereby offering a potential therapeutic target for the stabilization of carotid plaques.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!